Who can use Caprelsa(Vandetanib)?

Vandetanib effectively controls the growth and spread of tumors by inhibiting signaling pathways such as EGFR, VEGFR, and RET in tumor cells. 

Who can use Caprelsa(Vandetanib)?

It is indicated for the treatment of symptomatic or progressive medullary thyroid carcinoma that is unresectable, locally advanced, or metastatic, and is also used in lung cancer patients with specific gene mutations.

Vandetanib is an oral multi-target tyrosine kinase inhibitor. It mainly prevents the growth, angiogenesis, and metastasis of tumor cells by selectively inhibiting multiple important receptors and kinases. These targets include epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), RET kinase, etc. By interfering with key regulatory factors in the tumor microenvironment, vandetanib can delay tumor progression. It is mainly used for the treatment of unresectable advanced or metastatic medullary thyroid carcinoma (MTC) and significantly prolongs patients' progression-free survival (PFS).